Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomatrop Injection Pain Non-inferiority Study
NCT03634514Phase 4Unknown
- Sponsor
- Aché Laboratórios Farmacêuticos
- Start
- Aug 2018
- Primary completion
- Sep 2018
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Biomatrop in growth hormone deficiency (GHD) (2 arms), sponsored by Aché Laboratórios Farmacêuticos. Primary endpoint: Pain Intensity at 1 hour. Status: unknown.
02
Drugs
Biomatrop
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT03634514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03634514.